<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469416</url>
  </required_header>
  <id_info>
    <org_study_id>11-07522</org_study_id>
    <nct_id>NCT01469416</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Clopidogrel and Rosuvastatin</brief_title>
  <official_title>The Effects of Administering Clopidogrel on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if clopidogrel inhibits hepatic uptake transport of&#xD;
      rosuvastatin clinically.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-concentration curve (AUC) of rosuvastatin</measure>
    <time_frame>Blood samples collected over a 48 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of rosuvastatin</measure>
    <time_frame>predose, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to concentration maximum (Tmax) of rosuvastatin</measure>
    <time_frame>predose, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin + clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg PO x 1</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Rosuvastatin + clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)</description>
    <arm_group_label>Rosuvastatin + clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy individuals, male or female, age 18-65 years old, with no current medical&#xD;
             conditions or active diagnoses as determined by the study doctor based on history,&#xD;
             physical exam and laboratory evaluations&#xD;
&#xD;
          -  Subjects that take no other medications 2 weeks prior to the study and during the time&#xD;
             course of the study including prescription medications, over-the-counter medications&#xD;
             (except acetaminophen), dietary supplements, or drugs of abuse&#xD;
&#xD;
          -  Subjects with a SLCO1B1*1A genotype&#xD;
&#xD;
          -  Subjects able to maintain adequate birth control during the study independent of&#xD;
             hormonal contraceptive use&#xD;
&#xD;
          -  Subjects able to abstain from grapefruit, grapefruit juice, orange juice, caffeinated&#xD;
             beverages and/or alcoholic beverages from 3 pm the day before the study to completion&#xD;
             of that study day.&#xD;
&#xD;
          -  Participants determined to have normal liver and kidney function as measured at&#xD;
             baseline&#xD;
&#xD;
          -  BMI between 18.5 - 30 kg/m2&#xD;
&#xD;
          -  Subjects capable of fasting from food and beverages at least 8 hours prior to&#xD;
             medication dosing&#xD;
&#xD;
          -  Be able to read, speak, and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with active medical problems&#xD;
&#xD;
          -  Subjects on chronic prescription or OTC medications that cannot be stopped 2 weeks&#xD;
             prior to and during the study.&#xD;
&#xD;
          -  Subjects incapable of multiple blood draws (HCT &lt;30 mg/dL)&#xD;
&#xD;
          -  Subjects with a history of rhabdomyolysis&#xD;
&#xD;
          -  Subjects with a history of drug-related myalgias&#xD;
&#xD;
          -  Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias&#xD;
&#xD;
          -  Subjects with a history of GI bleed or peptic ulcer disease&#xD;
&#xD;
          -  Subjects with a recent history of trauma&#xD;
&#xD;
          -  Subjects with a recent history of or upcoming plan of surgery&#xD;
&#xD;
          -  Subjects that smoke tobacco or have ongoing alcohol or illegal drug use&#xD;
&#xD;
          -  Subjects who are pregnant, lactating, or trying to conceive during the study period&#xD;
&#xD;
          -  Subjects allergic to rosuvastatin or clopidogrel or any known component of the&#xD;
             medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Center, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug interaction</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>drug transporter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

